• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

    6.620 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about DiaMedica Therapeutics Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 Next >
    News headline image
    DiaMedica (DMAC) Q2 2026 Earnings Call Transcript ↗
    ReMEDy2 stroke trial nears interim analysis with 85% enrollment complete. 
    Via The Motley Fool
    Topics Earnings
    News headline image
    DiaMedica Therapeutics Q2 Earnings Call Highlights ↗
    DiaMedica Therapeutics (NASDAQ:DMAC) said its second-quarter progress centered on advancing DM199 across early-onset fetal growth restriction (FGR), preeclampsia and acute ischemic stroke, while the... 
    Via MarketBeat
    Topics Earnings
    News headline image
    DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    DiaMedica Therapeutics (NASDAQ:DMAC) Posts Wider Q1 Loss but Clinical Catalysts Fuel Stock Resilience ↗
    Via Chartmill
    News headline image
    Earnings Scheduled For November 12, 2025 ↗
     
    Via Benzinga
    News headline image
    DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    News headline image
    DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    News headline image
    DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    News headline image
    DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    News headline image
    DiaMedica (DMAC) Q4 2025 Earnings Transcript ↗
    DiaMedica (DMAC) Q4 2025 Earnings Transcript 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    News headline image
    DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    News headline image
    DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    News headline image
    DiaMedica (DMAC) Q1 2026 Earnings Transcript ↗
    DiaMedica (DMAC) Q1 2026 Earnings Transcript 
    Via The Motley Fool
    Topics Death
    News headline image
    DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    News headline image
    DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    News headline image
    RedChip's Biotech Virtual Investor Conference Replays Now Available
    Via ACCESS Newswire
    News headline image
    RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
    Via ACCESS Newswire
    News headline image
    DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    News headline image
    Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings ↗
    DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarterly loss of 18 cents per share. Stock fell 0.9% on Friday. 
    Via Benzinga
    News headline image
    DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    News headline image
    DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
    From DiaMedica Therapeutics Inc
    Via Business Wire
    News headline image
    DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    News headline image
    DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    News headline image
    DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
     
    Via Benzinga
    News headline image
    DiaMedica Therapeutics Inc (NASDAQ:DMAC) Reports Q3 2025 Earnings and Clinical Progress ↗
    DiaMedica reports Q3 2025 results, advancing DM199 for stroke and preeclampsia. The company has a cash runway into H2 2027 to fund clinical trials. 
    Via Chartmill
    News headline image
    DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    News headline image
    An Overview of DiaMedica Therapeutics's Earnings ↗
     
    Via Benzinga
    News headline image
    DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
    From DiaMedica Therapeutics Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.